AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02638376 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: simultaneous KXL and topography-guided transepithelial photorefractive keratectomy(PRK)
Description: The (Partial, Spherically Corrected) Topography-guided Transepithelial PRK Technique. Is performed with WaveLight® EX 500 excimer laser (Alcon Laboratories Inc, Ft Worth, Texas) customized platform.~This software utilizes topographic data from the linked topography device (Topolyzer; Wave- Light GmbH, Erlangen, Germany). The image of the planned surgery is generated by the laser software.~The topography-guided PRK is used to normalize the cornea by reducing irregular astigmatism while treating part of the refractive error. The maximum ablation depth of stromal ablation is set at 50um.~A 6.5-mm, 50-μm phototherapeutic keratectomy (PTK) was performed to remove the corneal epithelium. Partial topography- guided PRK laser treatment was applied. A cellulose sponge soaked in mitomycin C (MMC) 0.02% solution was applied over the ablated tissue for 20 seconds followed by irrigation with 10 mL of chilled balanced salt solution.
Study NCT00601133 — intervention group
Intervention type: BEHAVIORAL
Intervention: Diary
Description: Record any physical exercise done from departure of rehabilitation center to return visit 1 month later; includes exercises; approximately 5 minutes per entry
Study NCT04533828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI-04
Description: Each subject receive a single intravenous injection of 68Ga-FAPI-04, and undergo PET/CT scanning within the specified time.
Study NCT00414583 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Observational study, only laboratory analysis and diagnostic interventions done; no drug tested
Study NCT02892201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: a constant dose of 200 mg every three weeks, for four cycles.
Study NCT03595423 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical AVR with bioprosthetic or mechanical prosthesis
Description: Surgical AVR with bioprosthetic or mechanical prosthesis
Study NCT02455999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYL1001
Description: SYL1001 eye drops dose C administration for 10 consecutive days
Study NCT02455999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYL1001
Description: SYL1001 eye drops dose D administration for 10 consecutive days
Study NCT02455999 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo eye drops administration for 10 consecutive days
Study NCT04247269 — intervention group
Intervention type: OTHER
Intervention: Enteral Tube Feeding
Description: Enteral tube feeding
Study NCT03415399 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ET190L1 ARTEMIS™ T cells
Description: Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) ARTEMIS™ expression construct
Study NCT03384771 — intervention group
Intervention type: BEHAVIORAL
Intervention: MBSR
Description: There is no study intervention per se, but participants will be teaching or enrolled in public 8-week MBSR classes.
Study NCT01944449 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein (WPC) at breakfast
Description: The type 2 diabetic subjects in Whey Protein (WPC) group will consume at breakfast WPC (35 g) in 250ml of milk, Total 42 g protein breakfast for 12 weeks.
Study NCT01944449 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Other Protein Sources at breakfast
Description: The type 2 diabetic subjects in PBdiet will consume also 42 g of protein but from different sources : i.e soy,tuna, eggs, at breakfast in bottle mixed with 250 ml water twice a day (30 min before breakfast and before dinner) for 12 weeks.
Study NCT01944449 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low Protein at breakfast
Description: The type 2 diabetic subjects in CBdiet group will consume only 17 g protein, namely from at breakfast for 12 weeks.
Study NCT02680197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF5259 or Placebo administration
Description: Administration of 2 puffs of treatment in the morning and in the evening during a 4 week period. Each patient will be allocated to 3 out of the 5 possible treatments.
Study NCT02680197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CHF5259 or Placebo administration
Description: Administration of 2 puffs of treatment in the morning and in the evening during a 4 week period. Each patient will be allocated to 3 out of the 5 possible treatments.
Study NCT00336323 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Photocoagulation
Description: Laser photocoagulation at baseline; If edema present at 12 weeks, can be treated with 2 intravitreal injections of 1.25 mg bevacizumab spaced 6 weeks apart
Study NCT00336323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 1.25 mg intravitreal injection of bevacizumab at baseline and 6 weeks
Study NCT00336323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 2.5 mg intravitreal injection of bevacizumab at baseline and 6 weeks
Study NCT00336323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 1.25 mg intravitreal injection of bevacizumab at baseline (sham injection at 6 weeks)
Study NCT02206932 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sofosbuvir + Simeprevir
Study NCT02509988 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Study nutritional drink
Description: Study nutritional drink containing a mix of micronutrients, probiotics and myo-inositol.
Study NCT02509988 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard nutritional drink
Description: Standard nutritional drink containing a mix of micronutrients.
Study NCT03046381 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tocilizumab
Description: Tocilizumab 162mg 1x weekly s.c.
Study NCT03010345 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osmed self inflating tissue expanders
Description: Osmed self inflating tissue expanders will be placed 21 days before bone grafting the cleft to gain soft tissue coverage
Study NCT03010345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iliac bone graft
Description: Bone grafting the cleft without the use of osmed self inflating tissue expander
Study NCT03582345 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EEG/fMRI
Description: All the patients recruited will undergo to the following interventions:~1. Presurgical assesment protocol of the recruited patients (RU1 and RU2) that will includes: (a) detailed medical and epilepsy patients' history; (b) neurologic evaluation; (c) structural 3 Tesla MRI; (d) prolonged video-EEG monitoring including one-overnight EEG recording; (e) neuropsychological evaluation including quality of life evaluation. 2. EEG-fMRI coregistration: All subjects will undergo to a Video-EEG/fMRI study. This protocol will include a 32-channels EEG recorded simultaneously to fMRI data acquisition (3T scanner, Philips). This phase will be articulated in two steps: (i) acquisition of the EEG-fMRI data; (ii) fMRI data analysis (conventional and DCM analysis). RU1 will be charged for both steps. 3. Surgical resection of the epileptic foci and/or intracranial electrode recording (icEEG). The DRE patients in whom an intracranial recording will be considered unnecessary, will be operated at the RU2.
Study NCT03272529 — intervention group
Intervention type: OTHER
Intervention: Patient-specific simulated rehearsals
Description: Using 3-D printing and polymer technology, the investigators' team will construct patient-specific simulated hydrogel models designed from patients' imaging, incorporating the necessary anatomy, physiology, and pathology specific to each patient. These models will be constructed at the Simulation Innovation laboratory within the Department of Urology, University of Rochester. The process involves importing DICOM files of patient participants C.T. scans into 3D processing software, creating virtual models of kidney parenchyma incorporating the kidney, urinary system, stone and abdominal wall. Surgical phantoms are then created using 3D printing and polymer hydrogels, to recreate the entire procedure.
Study NCT03272529 — intervention group
Intervention type: OTHER
Intervention: Idealized simulated rehearsals
Description: Using 3D printing and polymer technology, the investigators' team will construct a validated generic simulated hydrogel model with a complex kidney stone, incorporating the necessary anatomy, physiology and pathology. These models will be constructed at the Simulation Innovation laboratory within the department of urology at the University of Rochester. Generic models incorporating the kidney, PCS, staghorn stone, abdominal wall, and other relevant anatomical elements (bowel, perinephric fat, solid organs and bony structures) will be constructed. Participants in his group will complete the simulation replicating all steps of the procedure of this ideal training case that is not specific to a particular patient.
Study NCT03272529 — intervention group
Intervention type: OTHER
Intervention: Standard simulation
Description: Participants recruited to this cohort will only have completed the standard prerequisite simulation training similar to the two other groups (didactic lecture, hands-on simulation training to proficiency and live case observation), that represents the current standard of care. No further simulation would be conducted in participants of this group in addition to the standard.
Study NCT01677949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Days 1-5: Clofarabine 30 mg/m\^2 for 0-30 years of age or 20 mg/m\^2 for > 30 years of age intravenously (IV) over 2 hours
Study NCT01677949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Days 1-5: Etoposide 100mg/m\^2 IV over 2 hours
Study NCT01677949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days 1-5: Cyclophosphamide 300 mg/m\^2 as a 30-60 minute infusion
Study NCT01677949 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic cell transplantation
Description: Between Days 28 and 42: infused independent of this study
Study NCT00336323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 1.25 mg intravitreal injection of bevacizumab at baseline, laser photocoagulation at 3 weeks, and intravitreal injection of 1.25 mg bevacizumab at 6 weeks
Study NCT04746365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin
Description: ivermectin is anthelmintic
Study NCT04746365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: hydroxychloroquine is antimalarial.
Study NCT04746365 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard treatments
Study NCT02927002 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive brain stimulation
Study NCT02927002 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Noninvasive brain stimulation
Study NCT02419209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose pillules medicated with the Individualised Homeopathic Remedy
Description: Sucrose pillules medicated with the Individualised Homeopathic Remedy and potency as selected by the researcher in accordance with the laws that govern individualised homeopathic prescribing.
Study NCT02572115 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Akutknappen - used
Description: A caller chooses to bypass the telephone waiting line by pressing the emergency access button
Study NCT02572115 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Akutknappen - not used
Description: A caller chooses NOT to bypass the telephone waiting line.
Study NCT01069328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar (Sorafenib, BAY43-9006)
Description: Sorafenib 200 mg orally BID interrupted dosing
Study NCT01069328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar (Sorafenib, BAY43-9006)
Description: Sorafenib 400 mg orally BID interrupted dosing
Study NCT01069328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 2.5 mg/kg intravenously
Study NCT01069328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 5 mg/kg intravenously
Study NCT01069328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 7.5 mg/kg intravenously
Study NCT01069328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10 mg/kg intravenously
Study NCT01069328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m² intravenously
Study NCT01069328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 6 intravenously
Study NCT02867098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb5871
Study NCT03065998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opipramol
Description: PO
Study NCT03065998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: PO
Study NCT01880437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Cohort 2: 20 mg sc daily for 10 days starting Day 1, with a possible further cycle of 20 mg sc daily for 5 days starting no earlier than Day 29
Study NCT01880437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vismodegib
Description: Cohorts 1 and 2: 150 mg orally daily
Study NCT03352882 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultrasound
Description: Hepatic ultrasound using gray scale, color Doppler, and spectral Doppler imaging to evaluate hepatic vein and portal vein patency, direction and velocity of flow respectively. ARFI will be performed in the right hepatic lobe. Three measurements of stiffness (m/s) will be performed and the mean value recorded.
Study NCT00005064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT04410549 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT)
Description: To perform OCT in pulmonary artery of patient with COVID-19
Study NCT04622371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate exercises
Description: Group 1 received 30 minutes of aerobic exercise at 40-60% of maximum heart rate. Group 2,Treated by walking30 minutes daily divided into 5minutes every 2 hours to break sedentary position for 12 hours daily.
Study NCT01930214 — intervention group
Intervention type: DEVICE
Intervention: Percutaneous Coronary Intervention
Description: Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).
Study NCT02550912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: vitamin D drops for paediatrics
Study NCT02550912 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: glucose syrup with same taste and color to vitamin D3 drops
Study NCT03589300 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Persona TM Tibia
Description: Trabecular Metal tibia used in primary cementless total knee arthroplasty
Study NCT04947436 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Frequency Chest Wall Oscillation
Description: The HFCWO aims to mobilize the secretions to the pharynx to allow the patient to expel the secretions. However, many ALS patients are unable to expel their secretions due to atrophied expiratory muscles. The HFCWO device uses a small air compressor with a vest that wraps around the chest to induce airflows that pull secretions from the walls of the airways, thin the secretions and move them up the airways towards the larger airways and pharynx.
Study NCT04947436 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical insufflation/exsufflation
Description: A noninvasive therapy, removes secretions in patients who have an ineffective cough because their peak cough flows are less than 270 L/min. This device applies a positive pressure to the airway and rapidly switches to a negative pressure applied to the airway. The rapid switch between the two types of pressure simulates a natural cough, thus assisting with expulsion of the secretions.
Study NCT00673127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole, Hydrocortisone and Dutasteride
Description: Ketoconazole: 200mg orally three times a day on an empty stomach. Hydrocortisone: 30mg in the morning and 10mg in the evening. Pills should be taken with food or milk.~Dutasteride: 0.5mg orally once a day on an empty stomach or after eating a meal
Study NCT00020709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00020709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT00020709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00020709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given orally
Study NCT00020709 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study NCT00020709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally
Study NCT02661503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin
Study NCT02661503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Study NCT02661503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT02661503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Study NCT02661503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Study NCT02661503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Study NCT02661503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT02661503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Study NCT02661503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Procarbazine
Study NCT02661503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Study NCT02661503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Study NCT02661503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Study NCT02661503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT02068196 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling for Pre-existing immunity
Description: Identify predictive biomarkers of long term study survivors who have substantially benefited from ipilimumab therapy
Study NCT02068196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT02109107 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia EZ6 Laser
Description: The Erchonia EZ6 is administered 6 times across 6 consecutive weeks, each administration seven days apart, each treatment lasting 60 minutes.
Study NCT03168399 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PKU Explore
Description: PKU Explore is an unflavoured, powdered, phenylalanine-free, protein substitute, containing essential and non-essential amino acids, carbohydrate, sugar, vitamins, minerals, trace elements and the long chain polyunsaturated fatty acids (LCPs); arachidonic acid (AA) and docosahexaenoic acid (DHA).
Study NCT01412632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil, propofol and citanest
Description: iv remifentanil iv propofol im citanest
Study NCT01324700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High severity group: Escitalopram
Description: Participants within high severity group were stratified to receive escitalopram.
Study NCT01324700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: High severity group: Placebo
Description: Participants within high severity group were stratified to receive placebo (inactive ingredient matching the active medication in appearance).
Study NCT01324700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low severity group: Escitalopram
Description: Participants within low severity group were stratified to receive escitalopram.
Study NCT01324700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low severity group: Placebo
Description: Participants within low severity group were stratified to receive placebo (inactive ingredient matching the active medication in appearance).
Study NCT02251756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actinica, 0.8 mg/cm2, 1 application
Study NCT02251756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actinica, 0.8 mg/cm2, 2 applications
Study NCT02251756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actinica, 2 mg/cm2, 1 application
Study NCT02251756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actinica, 2 mg/cm2, 2 applications
Study NCT03299413 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wharton Jelly Mesenchymal stem cells
Description: Wharton Jelly Mesenchymal stem cells will be injected intravenously